tiprankstipranks
Bridgebio Pharma (BBIO)
NASDAQ:BBIO
US Market
BBIO
BridgeBio Pharma
RESEARCH TOOLSreports
Want to see BBIO full AI Analyst Report?

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

1,481 Followers
See the Price Targets and Ratings of:

BBIO Analyst Ratings

Strong Buy
18Ratings
Strong Buy
16 Buy
2 Hold
0 Sell
Based on 18 analysts giving stock ratings to
BridgeBio
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BBIO Stock 12 Month Forecast

Average Price Target

$106.35
▲(38.57% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for BridgeBio Pharma in the last 3 months. The average price target is $106.35 with a high forecast of $157.00 and a low forecast of $82.00. The average price target represents a 38.57% change from the last price of $76.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"$34","65":"$65","96":"$96","127":"$127","158":"$158"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$157.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.35294117647058,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,65,96,127,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.56,75.36307692307693,82.16615384615385,88.96923076923078,95.77230769230769,102.57538461538462,109.37846153846155,116.18153846153847,122.98461538461538,129.7876923076923,136.59076923076924,143.39384615384614,150.1969230769231,{"y":157,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.56,71.46714932126697,74.37429864253394,77.2814479638009,80.18859728506787,83.09574660633484,86.00289592760181,88.91004524886878,91.81719457013574,94.72434389140271,97.63149321266968,100.53864253393664,103.44579185520362,{"y":106.35294117647058,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.56,69.59384615384616,70.62769230769231,71.66153846153847,72.69538461538461,73.72923076923077,74.76307692307692,75.79692307692308,76.83076923076923,77.86461538461539,78.89846153846153,79.93230769230769,80.96615384615384,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.37,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.49,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.24,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.56,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$157.00Average Price Target$106.35Lowest Price Target$82.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on BBIO
Eric Joseph
J.P. Morgan
J.P. Morgan
$82
Hold
6.84%
Upside
Initiated
05/19/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO) and Cullinan Management (NASDAQ: CGEM)
Citi Analyst forecast on BBIO
Unknown Analyst
Citi
Not Ranked
Citi
$82
Hold
6.84%
Upside
Initiated
05/15/26
BridgeBio initiated with a Neutral at CitiBridgeBio initiated with a Neutral at Citi
Bank of America Securities Analyst forecast on BBIO
Jason Zemansky
Bank of America Securities
Bank of America Securities
$96→$101
Buy
31.60%
Upside
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI)
William Blair Analyst forecast on BBIO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (NASDAQ: CRDL) and BridgeBio Pharma (NASDAQ: BBIO)
Piper Sandler Analyst forecast on BBIO
Biren Amin
Piper Sandler
Piper Sandler
$111
Buy
44.63%
Upside
Reiterated
05/12/26
Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
H.C. Wainwright Analyst forecast on BBIO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$100→$110
Buy
43.32%
Upside
Reiterated
05/11/26
BridgeBio price target raised to $110 from $100 at H.C. WainwrightBridgeBio price target raised to $110 from $100 at H.C. Wainwright
Truist Financial Analyst forecast on BBIO
Danielle Brill
Truist Financial
Truist Financial
$102
Buy
32.90%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Codexis (NASDAQ: CDXS), Irhythm Technologies (NASDAQ: IRTC) and BridgeBio Pharma (NASDAQ: BBIO)
Barclays Analyst forecast on BBIO
Eliana Merle
Barclays
Barclays
$157
Buy
104.56%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS), BridgeBio Pharma (NASDAQ: BBIO) and Globus Medical (NYSE: GMED)
Wells Fargo Analyst forecast on BBIO
Derek Archila
Wells Fargo
Wells Fargo
$98
Buy
27.69%
Upside
Reiterated
05/09/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and BridgeBio Pharma (NASDAQ: BBIO)
Evercore ISI Analyst forecast on BBIO
Cory Kasimov
Evercore ISI
Evercore ISI
$125→$130
Buy
69.38%
Upside
Reiterated
05/08/26
BridgeBio price target raised to $130 from $125 at Evercore ISIBridgeBio price target raised to $130 from $125 at Evercore ISI
Morgan Stanley Analyst forecast on BBIO
Sean Laaman
Morgan Stanley
Morgan Stanley
$98→$94
Buy
22.48%
Upside
Reiterated
05/08/26
BridgeBio price target lowered to $94 from $98 at Morgan StanleyBridgeBio price target lowered to $94 from $98 at Morgan Stanley
Goldman Sachs Analyst forecast on BBIO
Paul Choi
Goldman Sachs
Goldman Sachs
$112→$116
Buy
51.14%
Upside
Reiterated
05/08/26
BridgeBio Pharma (BBIO) Receives a Buy from Goldman Sachs
Bernstein Analyst forecast on BBIO
William Pickering
Bernstein
Bernstein
$100→$114
Buy
48.53%
Upside
Reiterated
05/08/26
Bernstein Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TD Cowen Analyst forecast on BBIO
Tyler Van Buren
TD Cowen
TD Cowen
$60→$95
Buy
23.78%
Upside
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on BBIO
Luca Issi
RBC Capital
RBC Capital
$100
Buy
30.29%
Upside
Reiterated
05/07/26
RBC Capital Remains a Buy on BridgeBio Pharma (BBIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on BBIO
Eric Joseph
J.P. Morgan
J.P. Morgan
$82
Hold
6.84%
Upside
Initiated
05/19/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO) and Cullinan Management (NASDAQ: CGEM)
Citi Analyst forecast on BBIO
Unknown Analyst
Citi
Not Ranked
Citi
$82
Hold
6.84%
Upside
Initiated
05/15/26
BridgeBio initiated with a Neutral at CitiBridgeBio initiated with a Neutral at Citi
Bank of America Securities Analyst forecast on BBIO
Jason Zemansky
Bank of America Securities
Bank of America Securities
$96→$101
Buy
31.60%
Upside
Reiterated
05/13/26
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI)
William Blair Analyst forecast on BBIO
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (NASDAQ: CRDL) and BridgeBio Pharma (NASDAQ: BBIO)
Piper Sandler Analyst forecast on BBIO
Biren Amin
Piper Sandler
Piper Sandler
$111
Buy
44.63%
Upside
Reiterated
05/12/26
Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
H.C. Wainwright Analyst forecast on BBIO
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$100→$110
Buy
43.32%
Upside
Reiterated
05/11/26
BridgeBio price target raised to $110 from $100 at H.C. WainwrightBridgeBio price target raised to $110 from $100 at H.C. Wainwright
Truist Financial Analyst forecast on BBIO
Danielle Brill
Truist Financial
Truist Financial
$102
Buy
32.90%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Codexis (NASDAQ: CDXS), Irhythm Technologies (NASDAQ: IRTC) and BridgeBio Pharma (NASDAQ: BBIO)
Barclays Analyst forecast on BBIO
Eliana Merle
Barclays
Barclays
$157
Buy
104.56%
Upside
Assigned
05/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS), BridgeBio Pharma (NASDAQ: BBIO) and Globus Medical (NYSE: GMED)
Wells Fargo Analyst forecast on BBIO
Derek Archila
Wells Fargo
Wells Fargo
$98
Buy
27.69%
Upside
Reiterated
05/09/26
Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and BridgeBio Pharma (NASDAQ: BBIO)
Evercore ISI Analyst forecast on BBIO
Cory Kasimov
Evercore ISI
Evercore ISI
$125→$130
Buy
69.38%
Upside
Reiterated
05/08/26
BridgeBio price target raised to $130 from $125 at Evercore ISIBridgeBio price target raised to $130 from $125 at Evercore ISI
Morgan Stanley Analyst forecast on BBIO
Sean Laaman
Morgan Stanley
Morgan Stanley
$98→$94
Buy
22.48%
Upside
Reiterated
05/08/26
BridgeBio price target lowered to $94 from $98 at Morgan StanleyBridgeBio price target lowered to $94 from $98 at Morgan Stanley
Goldman Sachs Analyst forecast on BBIO
Paul Choi
Goldman Sachs
Goldman Sachs
$112→$116
Buy
51.14%
Upside
Reiterated
05/08/26
BridgeBio Pharma (BBIO) Receives a Buy from Goldman Sachs
Bernstein Analyst forecast on BBIO
William Pickering
Bernstein
Bernstein
$100→$114
Buy
48.53%
Upside
Reiterated
05/08/26
Bernstein Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TD Cowen Analyst forecast on BBIO
Tyler Van Buren
TD Cowen
TD Cowen
$60→$95
Buy
23.78%
Upside
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on BBIO
Luca Issi
RBC Capital
RBC Capital
$100
Buy
30.29%
Upside
Reiterated
05/07/26
RBC Capital Remains a Buy on BridgeBio Pharma (BBIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BridgeBio Pharma

3 Months
Greg HarrisonScotiabank
Success Rate
14/16 ratings generated profit
88%
Average Return
+29.51%
Copying Greg Harrison's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +29.51% per trade.
1 Year
Greg HarrisonScotiabank
Success Rate
13/16 ratings generated profit
81%
Average Return
+73.78%
Copying Greg Harrison's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +73.78% per trade.
2 Years
Greg HarrisonScotiabank
Success Rate
16/16 ratings generated profit
100%
Average Return
+114.49%
Copying Greg Harrison's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +114.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BBIO Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
9
12
16
17
Buy
24
36
43
36
26
Hold
0
0
0
0
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
45
55
52
46
In the current month, BBIO has received 43 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BBIO average Analyst price target in the past 3 months is 106.35.
Each month's total comprises the sum of three months' worth of ratings.

BBIO Financial Forecast

BBIO Earnings Forecast

Next quarter’s earnings estimate for BBIO is -$0.59 with a range of -$0.88 to -$0.40. The previous quarter’s EPS was -$0.84. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.
Next quarter’s earnings estimate for BBIO is -$0.59 with a range of -$0.88 to -$0.40. The previous quarter’s EPS was -$0.84. BBIO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Sales Forecast

Next quarter’s sales forecast for BBIO is $219.29M with a range of $194.40M to $248.81M. The previous quarter’s sales results were $194.51M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.
Next quarter’s sales forecast for BBIO is $219.29M with a range of $194.40M to $248.81M. The previous quarter’s sales results were $194.51M. BBIO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BBIO has Performed in-line its overall industry.

BBIO Stock Forecast FAQ

What is BBIO’s average 12-month price target, according to analysts?
Based on analyst ratings, Bridgebio Pharma’s 12-month average price target is 106.35.
    What is BBIO’s upside potential, based on the analysts’ average price target?
    Bridgebio Pharma has 38.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BBIO a Buy, Sell or Hold?
          Bridgebio Pharma has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Bridgebio Pharma’s price target?
            The average price target for Bridgebio Pharma is 106.35. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $157.00 ,the lowest forecast is $82.00. The average price target represents 38.57% Increase from the current price of $76.75.
              What do analysts say about Bridgebio Pharma?
              Bridgebio Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of BBIO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.